PDF(Pubmed)
Abstract：
Glioma is a prevalent type of malignant tumor. To date, there is a lack of literature reports that have examined the association between sulfatase modifying factor 1 (SUMF1) and glioma.
The levels of SUMF1 were examined, and their relationships with the diagnosis, prognosis, and immune microenvironment of patients with glioma were investigated. Cox and Lasso regression analysis were employed to construct nomograms and risk models associated with SUMF1. The functions and mechanisms of SUMF1 were explored and verified using gene ontology, cell counting kit-8, wound healing, western blotting, and transwell experiments.
SUMF1 expression tended to increase in glioma tissues. SUMF1 overexpression was linked to the diagnosis of cancer, survival events, isocitrate dehydrogenase status, age, and histological subtype and was positively correlated with poor prognosis in patients with glioma. SUMF1 overexpression was an independent risk factor for poor prognosis. SUMF1-related nomograms and high-risk scores could predict the outcome of patients with glioma. SUMF1 co-expressed genes were involved in cytokine, T-cell activation, and lymphocyte proliferation. Inhibiting the expression of SUMF1 could deter the proliferation, migration, and invasion of glioma cells through epithelial mesenchymal transition. SUMF1 overexpression was significantly associated with the stromal score, immune cells (such as macrophages, neutrophils, activated dendritic cells), estimate score, immune score, and the expression of the programmed cell death 1, cytotoxic T-lymphocyte associated protein 4, CD79A and other immune cell marker.
SUMF1 overexpression was found to be correlated with adverse prognosis, cancer detection, and immune status in patients with glioma. Inhibiting the expression of SUMF1 was observed to deter the proliferation, migration, and invasion of cancer cells. The nomograms and risk models associated with SUMF1 could predict the prognosis of patients with glioma.
The levels of SUMF1 were examined, and their relationships with the diagnosis, prognosis, and immune microenvironment of patients with glioma were investigated. Cox and Lasso regression analysis were employed to construct nomograms and risk models associated with SUMF1. The functions and mechanisms of SUMF1 were explored and verified using gene ontology, cell counting kit-8, wound healing, western blotting, and transwell experiments.
SUMF1 expression tended to increase in glioma tissues. SUMF1 overexpression was linked to the diagnosis of cancer, survival events, isocitrate dehydrogenase status, age, and histological subtype and was positively correlated with poor prognosis in patients with glioma. SUMF1 overexpression was an independent risk factor for poor prognosis. SUMF1-related nomograms and high-risk scores could predict the outcome of patients with glioma. SUMF1 co-expressed genes were involved in cytokine, T-cell activation, and lymphocyte proliferation. Inhibiting the expression of SUMF1 could deter the proliferation, migration, and invasion of glioma cells through epithelial mesenchymal transition. SUMF1 overexpression was significantly associated with the stromal score, immune cells (such as macrophages, neutrophils, activated dendritic cells), estimate score, immune score, and the expression of the programmed cell death 1, cytotoxic T-lymphocyte associated protein 4, CD79A and other immune cell marker.
SUMF1 overexpression was found to be correlated with adverse prognosis, cancer detection, and immune status in patients with glioma. Inhibiting the expression of SUMF1 was observed to deter the proliferation, migration, and invasion of cancer cells. The nomograms and risk models associated with SUMF1 could predict the prognosis of patients with glioma.
摘要：
背景：胶质瘤是一种常见的恶性肿瘤。迄今为止,缺乏研究硫酸酯酶修饰因子1(SUMF1)与神经胶质瘤之间关系的文献报道.
方法：检测SUMF1水平，以及它们与诊断的关系，预后,并对胶质瘤患者的免疫微环境进行了调查。Cox和Lasso回归分析用于构建与SUMF1相关的列线图和风险模型。利用基因本体论对SUMF1的功能和机制进行了探索和验证，细胞计数试剂盒-8，伤口愈合，西方印迹,和Transwell实验。
结果：SUMF1在胶质瘤组织中的表达有增加的趋势。SUMF1过表达与癌症的诊断有关，生存事件,异柠檬酸脱氢酶状态，年龄,和组织学亚型，并与胶质瘤患者的不良预后呈正相关。SUMF1过表达是预后不良的独立危险因素。SUMF1相关列线图和高风险评分可以预测胶质瘤患者的预后。SUMF1共表达基因参与细胞因子，T细胞激活,和淋巴细胞增殖。抑制SUMF1的表达可以阻止细胞增殖,迁移,并通过上皮间质转化对胶质瘤细胞进行侵袭。SUMF1过表达与基质评分显著相关，免疫细胞（如巨噬细胞，中性粒细胞，激活的树突状细胞），估计分数，免疫评分,并表达程序性细胞死亡因子1、细胞毒性T淋巴细胞相关蛋白4、CD79A等免疫细胞标志物。
结论：SUMF1过表达与不良预后相关，癌症检测,脑胶质瘤患者的免疫状态。观察到抑制SUMF1的表达以阻止增殖，迁移,和癌细胞的入侵。与SUMF1相关的列线图和风险模型可以预测胶质瘤患者的预后。
方法：检测SUMF1水平，以及它们与诊断的关系，预后,并对胶质瘤患者的免疫微环境进行了调查。Cox和Lasso回归分析用于构建与SUMF1相关的列线图和风险模型。利用基因本体论对SUMF1的功能和机制进行了探索和验证，细胞计数试剂盒-8，伤口愈合，西方印迹,和Transwell实验。
结果：SUMF1在胶质瘤组织中的表达有增加的趋势。SUMF1过表达与癌症的诊断有关，生存事件,异柠檬酸脱氢酶状态，年龄,和组织学亚型，并与胶质瘤患者的不良预后呈正相关。SUMF1过表达是预后不良的独立危险因素。SUMF1相关列线图和高风险评分可以预测胶质瘤患者的预后。SUMF1共表达基因参与细胞因子，T细胞激活,和淋巴细胞增殖。抑制SUMF1的表达可以阻止细胞增殖,迁移,并通过上皮间质转化对胶质瘤细胞进行侵袭。SUMF1过表达与基质评分显著相关，免疫细胞（如巨噬细胞，中性粒细胞，激活的树突状细胞），估计分数，免疫评分,并表达程序性细胞死亡因子1、细胞毒性T淋巴细胞相关蛋白4、CD79A等免疫细胞标志物。
结论：SUMF1过表达与不良预后相关，癌症检测,脑胶质瘤患者的免疫状态。观察到抑制SUMF1的表达以阻止增殖，迁移,和癌细胞的入侵。与SUMF1相关的列线图和风险模型可以预测胶质瘤患者的预后。
